JP7795459B2 - Ｐｄ－ｌ１に対する抗体およびその使用方法 - Google Patents

Ｐｄ－ｌ１に対する抗体およびその使用方法

Info

Publication number
JP7795459B2
JP7795459B2 JP2022532766A JP2022532766A JP7795459B2 JP 7795459 B2 JP7795459 B2 JP 7795459B2 JP 2022532766 A JP2022532766 A JP 2022532766A JP 2022532766 A JP2022532766 A JP 2022532766A JP 7795459 B2 JP7795459 B2 JP 7795459B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022532766A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021113307A5 (https=
JP2023504271A (ja
JP2023504271A5 (https=
Inventor
ウェイン エイ． マラスコ
マシュー チャン
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2023504271A publication Critical patent/JP2023504271A/ja
Publication of JPWO2021113307A5 publication Critical patent/JPWO2021113307A5/ja
Publication of JP2023504271A5 publication Critical patent/JP2023504271A5/ja
Priority to JP2025260144A priority Critical patent/JP2026048871A/ja
Application granted granted Critical
Publication of JP7795459B2 publication Critical patent/JP7795459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022532766A 2019-12-02 2020-12-02 Ｐｄ－ｌ１に対する抗体およびその使用方法 Active JP7795459B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025260144A JP2026048871A (ja) 2019-12-02 2025-12-17 Ｐｄ－ｌ１に対する抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962942455P 2019-12-02 2019-12-02
US62/942,455 2019-12-02
PCT/US2020/062815 WO2021113307A2 (en) 2019-12-02 2020-12-02 Antibodies against pd-l1 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025260144A Division JP2026048871A (ja) 2019-12-02 2025-12-17 Ｐｄ－ｌ１に対する抗体およびその使用方法

Publications (4)

Publication Number Publication Date
JP2023504271A JP2023504271A (ja) 2023-02-02
JPWO2021113307A5 JPWO2021113307A5 (https=) 2024-11-15
JP2023504271A5 JP2023504271A5 (https=) 2024-11-15
JP7795459B2 true JP7795459B2 (ja) 2026-01-07

Family

ID=76222467

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022532766A Active JP7795459B2 (ja) 2019-12-02 2020-12-02 Ｐｄ－ｌ１に対する抗体およびその使用方法
JP2025260144A Pending JP2026048871A (ja) 2019-12-02 2025-12-17 Ｐｄ－ｌ１に対する抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025260144A Pending JP2026048871A (ja) 2019-12-02 2025-12-17 Ｐｄ－ｌ１に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US20230127123A1 (https=)
EP (1) EP4069294A4 (https=)
JP (2) JP7795459B2 (https=)
AU (1) AU2020396896A1 (https=)
CA (1) CA3159308A1 (https=)
WO (1) WO2021113307A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN121620391A (zh) * 2023-04-06 2026-03-06 金麦安博股份有限公司 用于治疗癌症的针对pd-l1和cd137的多特异性结合剂
WO2025190373A1 (en) * 2024-03-14 2025-09-18 Topmunnity Therapeutics Taiwan Limited Chimeric antigen receptor against programmed death ligand 1 (pd-l1) and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150274835A1 (en) 2012-10-04 2015-10-01 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
US20170362297A1 (en) 2014-12-19 2017-12-21 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
US20190048085A1 (en) 2016-02-25 2019-02-14 Cell Medica Switzerland Ag Modified cells for immunotherapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20080280297A1 (en) * 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
US20110190157A1 (en) * 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
WO2015061341A1 (en) * 2013-10-21 2015-04-30 Accuro Technologies Inc. Double barrel syringe and method to use same for placement confirmation and joint space injection
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
WO2017143076A1 (en) * 2016-02-16 2017-08-24 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
EP3487883B1 (en) * 2016-07-20 2023-01-04 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
CN109906232B (zh) * 2016-09-23 2023-11-07 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
JP7269167B2 (ja) * 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
AU2019235900B2 (en) * 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150274835A1 (en) 2012-10-04 2015-10-01 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
US20170362297A1 (en) 2014-12-19 2017-12-21 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
US20190048085A1 (en) 2016-02-25 2019-02-14 Cell Medica Switzerland Ag Modified cells for immunotherapy

Also Published As

Publication number Publication date
EP4069294A2 (en) 2022-10-12
EP4069294A4 (en) 2024-07-10
CA3159308A1 (en) 2021-06-10
JP2026048871A (ja) 2026-03-17
JP2023504271A (ja) 2023-02-02
WO2021113307A3 (en) 2021-07-22
AU2020396896A1 (en) 2022-06-09
WO2021113307A2 (en) 2021-06-10
US20230127123A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
AU2013326901B2 (en) Human monoclonal anti-PD-L1 antibodies and methods of use
US11203646B2 (en) Anti-CD3 epsilon antibodies and methods of use thereof
US20240254234A1 (en) PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
JP2026048871A (ja) Ｐｄ－ｌ１に対する抗体およびその使用方法
JP2025121997A (ja) Ｐｄ－１に対する抗体およびその使用方法
WO2024173607A2 (en) Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
KR20240123846A (ko) Ctla-4에 대한 항체 및 이의 사용 방법
EP4688842A1 (en) Il-10 receptor antibodies and methods of use thereof
KR20250099103A (ko) Cldn4에 대한 항체 및 이의 사용 방법
JP7680967B2 (ja) Ｐｄ－１に対する抗体およびその使用方法
WO2025171401A2 (en) Antibodies against cd99 and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240226

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251219

R150 Certificate of patent or registration of utility model

Ref document number: 7795459

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150